Gastric inhibitory polypeptide (GIP) is an incretin hormone that helps regulate insulin, digestion, and fat storage. Learn how GIP works and why it matters.
Gastric inhibitory polypeptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is a hormone made by the small intestine that helps control blood sugar after a meal. It is one of the two major incretin hormones and triggers insulin release from the pancreas when glucose levels rise. GIP also slows stomach emptying, reduces stomach acid, and influences how the body stores fat.
What Is Gastric Inhibitory Polypeptide (GIP)?
GIP is a 42-amino acid hormone secreted by K cells that line the duodenum and upper jejunum, the first sections of the small intestine. Researchers identified it in the early 1970s and named it for its ability to block gastric acid secretion. The alternate name, glucose dependent insulinotropic polypeptide, came later, once scientists recognized that its main job is boosting insulin.
The hormone belongs to the gut polypeptide group known as incretins, along with GLP-1. Its polypeptide structure places it in the same family as glucagon and secretin, and its polypeptide function depends on binding to a dedicated receptor on the surface of target cells. Once released, GIP stays active in the bloodstream for only about five to seven minutes before the enzyme DPP-4 breaks it down.
The GIP Receptor: Where It Acts in the Body
The gastric inhibitory polypeptide receptor is a class B G protein-coupled receptor, which means it spans the cell membrane and signals through a molecule called cAMP. Receptors appear on pancreatic beta cells, fat cells, osteoblasts, the stomach lining, the heart, and parts of the brain.
That wide distribution explains why GIP has effects well beyond blood sugar. When GIP binds its receptor on a beta cell, the cell becomes more responsive to glucose and releases insulin. When it binds receptors on fat tissue, the cell takes up more fatty acids.
How GIP Controls Insulin and Blood Sugar
Roughly half to 70 percent of the insulin released after a meal comes from the incretin effect, and GIP is the dominant incretin in healthy people. The key phrase in glucose-dependent insulinotropic polypeptide is “glucose-dependent”: GIP only drives insulin release when blood sugar is already rising. That feature limits the risk of hypoglycemia from GIP alone.
In type 2 diabetes, GIP’s ability to boost insulin is often blunted, while GLP-1’s effect is better preserved. GIP can also stimulate glucagon release in certain situations, which is one reason researchers study both blocking and activating its receptor.
Effects Beyond Insulin: Digestion, Fat, and Bone
GIP does more than manage glucose, and its original name reflects one of those extra jobs.
- Stomach: GIP slows gastric emptying and reduces acid secretion, which may help nutrients enter the bloodstream more gradually.
- Fat tissue: GIP promotes fatty acid uptake and storage in adipocytes, an effect that has made it a target in obesity research.
- Bone: GIP receptors on osteoblasts point to a role in bone formation, and early research links the hormone to bone density.
- Brain and heart: GIP receptors appear in the brain and cardiovascular tissue, though their exact roles are still being mapped.
GIP vs. GLP-1: How the Two Incretins Compare
Both hormones are released from the gut after eating, but they differ in source, potency, and drug development.
| Feature | GIP | GLP-1 |
|---|---|---|
| Source cells | K cells (duodenum, jejunum) | L cells (ileum, colon) |
| Amino acids | 42 | 30 |
| Main actions | Insulin release, fat storage, gastric slowing | Insulin release, appetite suppression, slower gastric emptying |
| Effect in type 2 diabetes | Insulin response often blunted | Insulin response largely preserved |
| Appetite effect | Debated; may be modest | Well established |
| Drugs | Dual GIP/GLP-1 agonists; GIP antagonists in research | GLP-1 receptor agonists |
The distinction of polypeptide vs protein comes down to size—GIP and GLP-1 are short amino acid chains, while hemoglobin is a large, folded protein. Other polypeptide examples in the same hormonal family include glucagon, secretin, and amylin.
GIP in Medicine: Drugs and Research
Dual GIP/GLP-1 receptor agonists
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is the first FDA-approved drug that activates both the GIP and GLP-1 receptors. Clinical trials show substantial weight loss and blood sugar improvement with this dual approach.
GIP receptor antagonists
Counterintuitively, some researchers are testing drugs that block the GIP receptor instead of activating it, and animal studies suggest this can also reduce weight gain. The two strategies are not yet reconciled, and human data remain limited.
DPP-4 inhibitors
A class of diabetes drugs called DPP-4 inhibitors works by slowing the breakdown of GIP and GLP-1, extending the time both hormones stay active.
Safety and What to Know Before Considering Incretin Therapies
GIP itself is not sold or approved as a standalone treatment in the United States. Any drug that targets the GIP pathway is a prescription medication that should be used under medical supervision.
Common side effects of incretin-based drugs include nausea, vomiting, diarrhea, and reduced appetite, and serious risks such as pancreatitis and gallbladder disease have been reported. Anyone with a history of pancreatic, thyroid, or kidney problems should discuss risks with a healthcare professional before starting treatment. This article is general information and is not medical advice.
Frequently Asked Questions
What does gastric inhibitory polypeptide (GIP) do in the body?
GIP is an incretin hormone released by the small intestine after you eat. It stimulates insulin release from the pancreas when blood glucose rises, slows stomach emptying, reduces gastric acid, and promotes fatty acid storage in fat tissue. It also appears to influence bone formation.
Is GIP the same as GLP-1?
No. GIP and GLP-1 are two separate incretin hormones made by different intestinal cells. GIP comes from K cells in the duodenum and jejunum, while GLP-1 comes from L cells in the ileum and colon. GLP-1 has stronger effects on appetite and gastric emptying, while GIP plays a larger role in insulin release in healthy people.
What drugs target GIP?
Tirzepatide is the best-known example, a dual GIP and GLP-1 receptor agonist approved in the United States for type 2 diabetes and weight management. DPP-4 inhibitors indirectly raise GIP levels by slowing its breakdown. Researchers are also studying GIP receptor antagonists for obesity, but those compounds are not approved for human use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.